Other Events ·
Aclaris Therapeutics reports positive Phase 1b results for ATI-052 in atopic dermatitis and asthma
ACRSAclaris Therapeutics, Inc.
Aclaris Therapeutics announced primary analysis results from Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052. In severe atopic dermatitis, patients treated with ATI-052 experienced a 45% placebo-adjusted mean improvement in EASI scores and a 43% placebo-adjusted reduction in itch (PP-NRS) by day 57. In asthma, a single dose of ATI-052 resulted in a 59% mean reduction in fractional exhaled nitric oxide (FeNO) at day 15 and a 200 mL improvement in FEV1 compared to placebo. The compound demonstrated a favorable safety profile with no conjunctivitis observed. Aclaris intends to prioritize Phase 2b development of ATI-052 in eosinophilic esophagitis (EoE) starting early next year. Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases.